Page 102 - Human Bile Acid Metabolism: a Postprandial Perspective

Chapter 5
References
1. Al-Khaifi A, Rudling M, Angelin B. An FXR agonist reduces bile acid synthesis independently of increases in FGF19 in healthy volunteers. Gastroenterology 155: 1012–1016, 2018.
2. Angelin B, Björkhem I. Postprandial serum bile acids in healthy man. Evidence for differences in absorptive pattern between individual bile acids. Gut 18: 606–609, 1977.
3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131-2157, 2007.
4. Broeders EPM, Nascimento EBM, Havekes B, Brans B, Roumans KHM, Tailleux A, Schaart G, Kouach M, Charton J, Deprez B, Bouvy ND, Mottaghy F, Staels B, van Marken Lichtenbelt WD, Schrauwen P. The bile acid chenodeoxycholic acid increases human brown adipose tissue activity. Cell Metab 22: 418-426, 2015.
5. Brufau G, Stellaard F, Prado K, Bloks VWVWVW, Jonkers E, Boverhof R, Kuipers F, Murphy EJEJ. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52: 1455–1464, 2010.
6. Corvilain B, Abramowicz M, Féry F, Schoutens A, Verlinden M, Balasse E, Horowitz M. Effect of short-term starvation on gastric emptying in humans: relationship to oral glucose tolerance. Am J Physiol Gastrointest Liver Physiol 269: G512–G517, 1995.
7. DePaoli AM, Zhou M, Kaplan DD, Hunt SC, Adams TD, Learned RM, Tian H, Ling L. FGF19 analog as a surgical factor mimetic that contributes to metabolic effects beyond glucose homeostasis. Diabetes 68: 1315–1328, 2019.
8. Dutia R, Embrey M, O’Brien CS, Haeusler RA, Agénor KK, Homel P, McGinty J, Vincent RP, Alaghband-Zadeh J, Staels B, le Roux CW, Yu J, Laferrère B. Temporal changes in bile acid levels and 12α-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes 39: 806 –813, 2015 [Erratum in Int J Obes 40:554, 2016].
9. Eggink HM, van Nierop FS, Schooneman MG, Boelen A, Kalsbeek A, Koehorst M, ten Have GAM, de Brauw LM, Groen AK, Romijn JA, Deutz NEP, Soeters MR. Transhepatic bile acid kinetics in pigs and humans. Clin Nutr 37: 1406–1414, 2018.
10. Einarsson C, Hillebrant CG, Axelson M. Effects of treatment with deoxycholic acid and chenodeoxycholic acid on the hepatic synthesis of cholesterol and bile acids in healthy subjects. Hepatology 33: 1189–1193, 2001.
11. Einarsson K, Björkhem I, Eklöf R, Ewerth S, Nilsell K, Blomstrand R. Effect of ursodeoxycholic acid treatment on intestinal absorption of triglycerides in man. Scand J Gastroenterol 19: 283–288, 1984.
12. Frayn K. Calculation of substrate oxidation from gaseous exchange rates in vivo. J Appl Physiol Respir Environ Exerc Physiol 55: 628–634, 1983.
13. Friedrich D, Marschall H-U, Lammert F. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. BMC Gastroenterol 18: 76, 2018.
14. Glicksman C, Pournaras DJ, Wright M, Roberts R, Mahon D, Welbourn R, Sherwood R, Alaghband- Zadeh J, le Roux CW. Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem 47: 482–484, 2010.
15. von Haehling S, Schefold JC, Jankowska EA, Springer J, Vazir A, Kalra PR, Sandek A, Fauler G, Stojakovic T, Trauner M, Ponikowski P, Volk HD, Doehner W, Coats AJ, Poole-Wilson PA, Anker SD. Ursodeoxycholic acid in patients with chronic heart failure: a doubleblind, randomized, placebo- controlled, crossover trial. J Am Coll Cardiol 59: 585–592, 2012.
16. Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 62: 4184–4191, 2013.
17. Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab 15: 65–74, 2012.
18. Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, Loomba R. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391: 1174–1185, 2018.
100